Vafseo: Dosage Form, Projected Sales, NCE-1 Date | Vadadustat

Vafseo

Vafseo is an oral tablet that treats anemia in adults with chronic kidney disease on dialysis by boosting natural erythropoietin production through HIF‑prolyl hydroxylase inhibition. It minimizes the need for blood transfusions while carrying a caution for cardiovascular and clotting risks .

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Vadadustat
Innovator :

AKEBIA THERAPEUTICS INC
Approval Date :

27-Mar-24
NCE-1 Date :

27-Mar-28
NCE Date :

27-Mar-29
Dosage Form :

Oral Tablets
Strength :

150mg, 300mg and 450mg tablet
Therapeutic Category :

Antianemic
Revenue ($M) :

14

Year-wise Projected Sales ($M) :

2025 :

102
2026 :

231
2027 :

312
2028 :

408
2029 :

518
2030 :

619
2031 :

730

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Vafseo

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?